In this clinical trial round-up, we look at life sciences research and development announced during the week of 5th to 9th February, from early-stage onwards.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh